<DOC>
	<DOCNO>NCT00086541</DOCNO>
	<brief_summary>This Phase 3 clinical study design evaluate safety , tolerability , efficacy two dose level Infergen ( interferon alfacon-1 , CIFN ) plus Ribavirin administer daily 48 week treatment patient chronically infect hepatitis C nonresponders previous pegylated interferon alfa plus ribavirin therapy . Patients randomize 1:1:1 receive Interferon Alfacon-1 ( 9 15 µg ) + Ribavirin ( administer daily ) treatment 48 week . The protocol inform consent form use must approve Investigator ’ Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) study initiate .</brief_summary>
	<brief_title>Daily-Dose Consensus Interferon Ribavirin : Efficacy Combined Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon alfacon-1</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>( Abbreviated due space constraint . ) 1 . Signed informed consent form 2 . Male female 18 yr . age old 3 . Chronic HCV infection base documented history positive serum antiHCV antibody test and/or detectable level HCV RNA 4 . Documented virologic nonresponse past treatment PEGASYS plus ribavirin PEGIntron plus ribavirin 5 . Previously treat w/either follow start dos pegylated interferon alpha : 1 . ≥ 1.5 µg/kg/week PEGIntron dose consistent package insert , 2 . ≥ 180 µg/week PEGASYS 6 . Detectable plasma HCV RNA level screen visit 7 . Liver biopsy histologically document chronic liver disease consistent chronic HCV infection 8 . All patient potentially fertile sexual partner patient must use 2 reliable form effective contraception study &amp; 6 month cessation study drug 1 . Any history decompensated liver disease 2 . Any variety laboratory abnormality assess blood sample screen 3 . Patients prematurely discontinue , interrupt , reduce dose previous pegylated interferon alphabased combination therapy due noncompliance safety and/or tolerability issue 4 . Patients undetectable HCV RNA level prior pegylated interferon alfa plus ribavirin treatment relapse followup 5 . Significant depression last 2 year 6 . Patients treat HCV infection within 3 month screen ( w/the exclusion overthecounter therapy ) 7 . Patients experimental protocol therapy within 28 day screen 8 . Use colonystimulating factor agent therapeutic agent might artificially elevate laboratory parameter within 3 month screen 9 . Known human immunodeficiency virus ( HIV ) infection positive HIV antibody test screen 10 . Chronic hepatitis B infection positive hepatitis B surface antigen ( HBsAg ) screen 11 . New onset diabetes 12 . Unstable uncontrolled thyroid disease 13 . Presence history nonHCV chronic liver disease 14 . History unstable deteriorate cardiac cerebrovascular disease within 6 month Screening 15 . Current history neurologic disorder within last 2 year 16 . History seizure within past 5 year 17 . History hemoglobinopathies 18 . History malignancy within last 5 year exception localize basal squamous cell carcinoma &amp; fully resect , localized malignancy require active treatment &amp; evidence recurrence 19 . A disease know cause significant alteration immunologic function include hematologic malignancy , sarcoidosis autoimmune disorder 20 . History evidence retinopathy 21 . History major organ transplantation exist functional graft 22 . Concurrent therapy immunosuppressive drug cytotoxic agent 23 . Alcohol and/or drug abuse w/in past year , opinion Investigator Sponsor may negatively affect patient compliance 24 . Pregnant lactate woman 25 . Male partner woman pregnant 26 . Known sensitivity Infergen IFNα E. coliderived product 27 . Patients , opinion Investigator Sponsor , suitable candidate enrollment would comply w/the requirement study 28 . Patients respond course daily Infergen ( 9 15 µg ) without ribavirin relapse course daily Infergen ( 9 15 µg ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Liver</keyword>
	<keyword>Pegylated</keyword>
	<keyword>Interferon</keyword>
	<keyword>Alpha</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Combination</keyword>
	<keyword>Nonresponder</keyword>
	<keyword>HCV</keyword>
	<keyword>Infergen</keyword>
	<keyword>SVR</keyword>
</DOC>